| (Values in U.S. Thousands) | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 |
| Sales | 45,000 | 48,290 | 43,310 | 38,300 | 33,450 |
| Sales Growth | -6.81% | +11.50% | +13.08% | +14.50% | -7.95% |
| Net Income | -45,080 | -47,190 | -49,580 | -48,560 | -49,610 |
| Net Income Growth | +4.47% | +4.82% | -2.10% | +2.12% | -7.99% |
Deciphera Pharmaceuticals Inc (DCPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary kinase switch control inhibitor platform.
Fiscal Year End Date: 12/31